Collaboration, License and Research Agreements - Additional Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2024	Jun. 30, 2023	Jun. 30, 2024	Jun. 30, 2023	Mar. 31, 2024	Dec. 31, 2023	Mar. 31, 2023	Dec. 31, 2022
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized	$ 2,045,000	$ 2,316,000	$ 5,588,000	$ 4,549,000
Deferred revenue	64,257,000	3,810,000	64,257,000	3,810,000	$ 66,302,000	$ 69,263,000	$ 5,057,000	$ 6,276,000
Research Collaboration, License Agreement and Securities Purchase Agreement with BMS
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized	2,000,000		4,500,000
Collaboration receivables	0		0			0
Research Collaboration and License Agreement with Eli Lilly
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items]
Revenue recognized	0	$ 2,300,000	1,100,000	$ 4,500,000
Collaboration receivables	0		0			$ 800,000
Deferred revenue	$ 0		$ 0